000303013 001__ 303013
000303013 005__ 20250727021619.0
000303013 0247_ $$2doi$$a10.1200/GO-25-00023
000303013 0247_ $$2pmid$$apmid:40644645
000303013 0247_ $$2ISSN$$a2378-9506
000303013 0247_ $$2ISSN$$a2687-8941
000303013 0247_ $$2altmetric$$aaltmetric:179455997
000303013 037__ $$aDKFZ-2025-01460
000303013 041__ $$aEnglish
000303013 082__ $$a610
000303013 1001_ $$00009-0008-5114-1600$$aAl Badarin, Essra'$$b0
000303013 245__ $$aExpanding the Pediatric Neuro-Oncology Teleconference Experience: From Twinning to International Cases Discussions.
000303013 260__ $$aAlexandria, VA$$bAmerican Society of Clinical Oncology$$c2025
000303013 3367_ $$2DRIVER$$aarticle
000303013 3367_ $$2DataCite$$aOutput Types/Journal article
000303013 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753095512_5171
000303013 3367_ $$2BibTeX$$aARTICLE
000303013 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303013 3367_ $$00$$2EndNote$$aJournal Article
000303013 520__ $$aVideo teleconferencing in neuro-oncology is feasible and sustainable. The well-established, 20-year long monthly teleconference between King Hussein Cancer Center (KHCC), Jordan, and SickKids, Canada, is an example. Since 2018, several regional centers joined these meetings to discuss their patients' management plans. We aim to evaluate this experience.We reviewed the minutes of 56 meetings (2018-2023). Preconference local treatment plans were compared with postconference recommendations. We documented the implementation of recommendations and the impact perceived by the treating oncologists.Two hundred fifty-one patients were discussed: 137 from Jordan and 114 from eight other countries. Four of the 14 participating oncologists had formal pediatric neuro-oncology training. Of the 227 patients (90%), where the local multidisciplinary team had suggested a preconference plan, the teleconference recommendations concurred with the proposed plan in 50% of cases, agreed on it and proposed an alternative option in 18%, and disagreed in 32%. The difference in recommendations mostly affected the proposed treatment modality. In 64% of discordant plans and 50% of alternative plans, the treating team applied the recommendations. The main challenges in applying the recommendations were attributed to patient-related factors (51%), local team consensus on a different plan (26%), or logistic difficulties (23%). The high patient load, longer involvement in teleconferencing, formal neuro-oncology training, and well-established multidisciplinary team helped the KHCC team formulate more concordant plans.This experience illustrates the potential benefit for physicians to get an expert opinion on challenging cases. The participating oncologists valued the shared educational experience, especially those related to molecular testing and treatment implications. Joining such regional teleconferences is of particular importance to centers with small patient volume or those lacking a pediatric neuro-oncologist.
000303013 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303013 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303013 650_2 $$2MeSH$$aHumans
000303013 650_2 $$2MeSH$$aChild
000303013 650_2 $$2MeSH$$aMedical Oncology: methods
000303013 650_2 $$2MeSH$$aFemale
000303013 650_2 $$2MeSH$$aMale
000303013 650_2 $$2MeSH$$aVideoconferencing
000303013 650_2 $$2MeSH$$aPediatrics: methods
000303013 650_2 $$2MeSH$$aJordan
000303013 650_2 $$2MeSH$$aAdolescent
000303013 7001_ $$00000-0002-8020-5588$$aChamdine, Omar$$b1
000303013 7001_ $$00000-0001-9791-0104$$aElayadi, Moatasem$$b2
000303013 7001_ $$00000-0001-8369-3348$$aAl-Battashi, Abeer$$b3
000303013 7001_ $$00000-0001-5780-5668$$aAl Nuaimi, Mohammed$$b4
000303013 7001_ $$00000-0002-5580-8723$$aAlshamsi, Eman Taryam$$b5
000303013 7001_ $$00000-0002-3322-273X$$aHessissen, Laila$$b6
000303013 7001_ $$00000-0002-8848-0998$$aAl-Tarrah, Hiba$$b7
000303013 7001_ $$00000-0001-5428-1555$$aMaher, Eslam$$b8
000303013 7001_ $$00000-0002-6392-1590$$aFarah, Roula$$b9
000303013 7001_ $$00000-0003-1399-5994$$aMaaz, Ata$$b10
000303013 7001_ $$aSaid, Waleed$$b11
000303013 7001_ $$aHazaimeh, Ruba$$b12
000303013 7001_ $$00009-0008-9625-7965$$aKhader, Maher$$b13
000303013 7001_ $$aSalami, Khadra$$b14
000303013 7001_ $$00000-0003-2618-4402$$aHawkins, Cynthia$$b15
000303013 7001_ $$00000-0002-8262-7469$$aAbdelbaki, Mohamed S$$b16
000303013 7001_ $$0P:(DE-He78)500a1860cab2d28ce2718dc7920c7587$$aBartels, Ute$$b17$$udkfz
000303013 7001_ $$00000-0002-5019-2683$$aTabori, Uri$$b18
000303013 7001_ $$00000-0002-6832-6539$$aBouffet, Eric$$b19
000303013 7001_ $$00000-0002-7972-5885$$aAmayiri, Nisreen$$b20
000303013 773__ $$0PERI:(DE-600)3018917-2$$a10.1200/GO-25-00023$$gVol. 11, no. 11, p. e2500023$$n11$$pe2500023$$tJCO global oncology$$v11$$x2378-9506$$y2025
000303013 909CO $$ooai:inrepo02.dkfz.de:303013$$pVDB
000303013 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)500a1860cab2d28ce2718dc7920c7587$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000303013 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303013 9141_ $$y2025
000303013 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-21T14:35:17Z
000303013 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-21T14:35:17Z
000303013 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-01-21T14:35:17Z
000303013 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJCO GLOB ONCOL : 2022$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-05
000303013 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-05
000303013 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000303013 980__ $$ajournal
000303013 980__ $$aVDB
000303013 980__ $$aI:(DE-He78)B310-20160331
000303013 980__ $$aUNRESTRICTED